Full history for every metric is available with a Kvantra account
Elbit Medical Technologies Ltd (EMTC-M.TA)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -39 | -39 | |||||
| Net profit | $m | -21 | 123 | -16 | -5 | -18 | 1 | 0 |
| EPS reported | $ | 0.01 | 0.00 | |||||
| Operating cashflow per share | $ | -0.01 | -0.00 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.01 | -0.00 | |||||
| Free cash flow | $m | -1 | -1 | |||||
| Net debt | $m | -1 | -1 | |||||
| Book value equity | $m | 8 | 8 | |||||
| Book value per share | $ | 0.09 | 0.09 | |||||
| Number of shares | m | 90.72 | 90.72 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 4.34 | - | |||||
| P/B LTM | x | 0.45 | 0.83 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -6.61 | -12.96 | |||||
| EV/EBITDA LTM | x | 0.00 | 0.00 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | 23.04% | -1.75% | |||||
| FCF Yield | % | -15.12% | -7.72% | |||||
| Quality | ||||||||
| ROE | % | 10.28% | -1.45% | |||||
| ROIC | % | -483.53% | -3.39% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -100.00% | -100.00% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 0.00 | 0.00 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -35.26% | -16.79% | |||||
| Net debt/Equity | x | -0.16 | -0.14 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Elbit Medical Technologies Ltd functions as an investment holding company, with its core activities centered on the innovation, production, and global commercialization of therapeutic medical devices. The company maintains a presence across the United States, Europe, and other international territories. A key initiative involves the advancement of a magnetic resonance imaging (MRI) guided focused ultrasound treatment system, designed to tackle a range of medical challenges, including various cancers (oncology), gynecological conditions, neurological disorders, and tumors. Additionally, Elbit Medical Technologies is engaged in the extensive study and creation of medical products leveraging stem cells, predominantly sourced from umbilical cord blood. These stem cell applications are critical for bone marrow transplants in individuals affected by leukemia, lymphatic system cancers, non-malignant hematological diseases, and inherited metabolic genetic conditions. Headquartered in Petah Tikva, Israel, Elbit Medical Technologies Ltd is a wholly-owned subsidiary of Exigent Management Ltd.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Elbit Medical Technologies Ltd (EMTC-M.TA)
Elbit Medical Technologies Ltd functions as an investment holding company, with its core activities centered on the innovation, production, and global commercialization of therapeutic medical devices. The company maintains a presence across the United States, Europe, and other international territories. A key initiative involves the advancement of a magnetic resonance imaging (MRI) guided focused ultrasound treatment system, designed to tackle a range of medical challenges, including various cancers (oncology), gynecological conditions, neurological disorders, and tumors. Additionally, Elbit Medical Technologies is engaged in the extensive study and creation of medical products leveraging stem cells, predominantly sourced from umbilical cord blood. These stem cell applications are critical for bone marrow transplants in individuals affected by leukemia, lymphatic system cancers, non-malignant hematological diseases, and inherited metabolic genetic conditions. Headquartered in Petah Tikva, Israel, Elbit Medical Technologies Ltd is a wholly-owned subsidiary of Exigent Management Ltd.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free